Companies

Gilead Starting Human Trials of an Inhaled Version of Remdesivir

Gilead Starting Human Trials of an Inhaled Version of Remdesivir
A vial of the investigational drug remdesivir is visually inspected at a Gilead manufacturing site in March 2020. Gilead Sciences/AP
Venus Upadhayaya
|Updated:

Gilead Sciences will begin human trials of an inhaled version of remdesivir this week.

“An inhaled formulation would be given through a nebulizer, which could potentially allow for easier administration outside the hospital, at earlier stages of the disease,” said Daniel O’Day, the Chairman and the CEO of Gilead Sciences in an open letter on June 22.
Venus Upadhayaya
Venus Upadhayaya
Reporter
Venus Upadhayaya reports on India, China, and the Global South. Her traditional area of expertise is in Indian and South Asian geopolitics. Community media, sustainable development, and leadership remain her other areas of interest.
twitter
Related Topics